Cover Image

Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk

Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT...

Full description

Saved in:
Bibliographic Details
Main Authors: Tian, Yu (Author) , Arndt, Volker (Author) , Brenner, Hermann (Author) , Hoffmeister, Michael (Author) , Chang-Claude, Jenny (Author)
Format: Article (Journal)
Language:English
Published: 01 April 2024
In: British journal of cancer
Year: 2024, Volume: 130, Issue: 10, Pages: 1687-1696
ISSN:1532-1827
DOI:10.1038/s41416-024-02638-2
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41416-024-02638-2
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41416-024-02638-2
Get full text
Author Notes:Yu Tian, Volker Arndt, Hermann Brenner, Michael Hoffmeister, Jenny Chang-Claude [und viele weitere]
Description
Summary:Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT on CRC risk.
Item Description:Gesehen am 10.07.2024
Physical Description:Online Resource
ISSN:1532-1827
DOI:10.1038/s41416-024-02638-2

Similar Items